Jeena Sikho LifecareNSE:JSLL +3.81%91 EBITDA Margin % is 37.73% as of Mar. 2026, which is 104% above its 10-year median of 18.48. GuruFocus rates NSE:JSLL with a GF Score™ of 91/100 and a GF Value™ of ₹771.14 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Jeena Sikho Lifecare ranks better than 96.86% on this metric.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Jeena Sikho Lifecare EBITDA Margin % Related Terms
Jeena Sikho Lifecare EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Jeena Sikho Lifecare's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:JSLL vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Jeena Sikho Lifecare's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jeena Sikho Lifecare EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Jeena Sikho Lifecare's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Jeena Sikho Lifecare's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jeena Sikho Lifecare (NSE:JSLL) has a EBITDA Margin % of 37.73% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jeena Sikho Lifecare and its competitors. This is 104% above median its historical median of 18.48. Over the past decade, Jeena Sikho Lifecare's EBITDA Margin % has ranged from 10.05 to 44.66. According to the industry distribution chart, Jeena Sikho Lifecare ranks #21 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 3.1%.
Is Jeena Sikho Lifecare's EBITDA Margin % too high?
Jeena Sikho Lifecare's current EBITDA Margin % of 37.73% is 104% above median its 10-year median of 18.48. Over the past 10 years, this metric has ranged from a low of 10.05 to a high of 44.66. The Healthcare Providers & Services industry median EBITDA Margin % is 10.21. Jeena Sikho Lifecare's value of 37.73% is 269.5% above this industry median. Based on the distribution chart, Jeena Sikho Lifecare ranks #21 out of 668 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, Jeena Sikho Lifecare has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jeena Sikho Lifecare's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Jeena Sikho Lifecare ranks #21 out of 668 companies for EBITDA Margin %. This places Jeena Sikho Lifecare in the top 3% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 10.21. Jeena Sikho Lifecare's value of 37.73% is 269.5% above this benchmark. Historically, Jeena Sikho Lifecare's own EBITDA Margin % has ranged from 10.05 to 44.66 over the past decade. While the company's 10-year median is 18.48 vs. the industry median of 10.21, Jeena Sikho Lifecare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jeena Sikho Lifecare's current EBITDA Margin % of 37.73% is 269.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Jeena Sikho Lifecare and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jeena Sikho Lifecare's current EBITDA Margin % is 37.73%, which is 104% above median its own 10-year median of 18.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jeena Sikho Lifecare stock overvalued right now?
Based on GuruFocus' analysis, Jeena Sikho Lifecare (NSE:JSLL) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹771.14, compared to a current price of ₹602.25 — trading 21.9% below its estimated fair value. The current EBITDA Margin % is 37.73%, which is 104% above median its 10-year median of 18.48 and 269.5% above the Healthcare Providers & Services industry median of 10.21. Jeena Sikho Lifecare's overall GF Score™ is 91/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Jeena Sikho Lifecare (NSE:JSLL), the current EBITDA Margin % is 37.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jeena Sikho Lifecare (NSE:JSLL) Overvalued in 2026?
Based on GuruFocus' analysis, Jeena Sikho Lifecare stock appears to be undervalued.
The current stock price of ₹602.25 is trading 21.9% below its estimated GF Value™ of ₹771.14.
GuruFocus considers Jeena Sikho Lifecare to be Modestly Undervalued.
Key valuation signals for NSE:JSLL:
EBITDA Margin %: 37.73% (104% above median its 10-year median of 18.48)
GF Value™: ₹771.14 vs. price of ₹602.25 (21.9% below fair value)
Industry Position: 269.5% above the Healthcare Providers & Services median (#21 of 668)
No single metric tells the full story. See the NSE:JSLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jeena Sikho Lifecare Ltd provides Ayurvedic healthcare products and services. The company operates only in one business segment which is Trading of Ayurvedic Medicines and providing Ayurvedic therapies. The company engages in conducting health check-up camps, and free yoga sessions to make people aware of health problems. It offers a wide range of Ayurvedic products such as Shuddhi 32 Herbs Tea, Shuddhi Addiction Free Kit, Shuddhi BP Package, Shuddhi Diabetes Care Package, and Shuddhi Divya Sanjeevani-Anti-Viral Package.
91GF Score
Get the complete analysis for NSE:JSLL
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:JSLL has been successfully added to your 
